What question did this study set out to answer?

The aim is to explore how ZRANB1 influences MYCN stability in neuroblastoma and its role as a therapeutic target.

April 10, 2026Open Access

ZRANB1 depletion inhibits neuroblastoma progression by destabilizing MYCN through EZH2-mediated deubiquitination

Key Points

The aim is to explore how ZRANB1 influences MYCN stability in neuroblastoma and its role as a therapeutic target.
Identified ZRANB1 as a deubiquitinase.
Examined the relationship between ZRANB1, EZH2, and MYCN.
Analyzed MYCN stability in MYCN-amplified neuroblastoma cells.
ZRANB1 depletion led to increased destabilization of MYCN.
EZH2 is identified as a regulatory intermediary in this process.
Establishing ZRANB1 as a therapeutic target shows potential for neuroblastoma treatment.

Abstract

This study identifies ZRANB1 as an upstream deubiquitinase that stabilizes EZH2, thereby indirectly maintaining MYCN stability in MYCN-amplified neuroblastoma. These findings establish a ZRANB1-EZH2-MYCN regulatory axis and highlight ZRANB1 as a promising therapeutic target in MYCN-amplified NB.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Zhichao Wang

Lei Cheng

Guanghui Li

Journals

Cell Biology and Toxicology

Actions

Institutions

Jilin University

First Hospital of Jilin University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

ZRANB1 depletion inhibits neuroblastoma progression by destabilizing MYCN through EZH2-mediated deubiquitination

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study